Hayati Yusof

Dr. Hayati Yusof


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Trends in Food Science & Technology
Verified
Journal Article
Closed access
NHN.R.A. Halim
N.R.A. Halim
HYHayati Yusof
Hayati Yusof
Norizah Mhd SarbonNorizah Mhd Sarbon
Norizah Mhd Sarbon

1 October 2018 in Biocatalysis and Agricultural Biotechnology
Verified
Journal Article
Closed access
NHNura Ruhaya Abdul Halim
Nura Ruhaya Abdul Halim
AAAzrina Azlan
Azrina Azlan
HYHayati Yusof
Hayati Yusof
Norizah Mhd SarbonNorizah Mhd Sarbon
Norizah Mhd Sarbon

1 March 2008 in Prostaglandins, Leukotrienes and Essential Fatty Acids
Verified
Journal Article
Closed access
HYHayati Yusof
Hayati Yusof
EMElizabeth A Miles
Elizabeth A Miles
PCPhilip Calder
Philip Calder

1 December 2018 in Molecular Aspects of Medicine
Verified
Journal Article
Closed access
EBElla J. Baker
Ella J. Baker
HYHayati Yusof
Hayati Yusof
PYParveen Yaqoob
Parveen Yaqoob
EMElizabeth A Miles
Elizabeth A Miles
PCPhilip Calder
Philip Calder

30 December 2021 in Medicina
Verified
Journal Article
Open access
PDF file
AMAtiah Munirah Meli
Atiah Munirah Meli
AAAsma' Ali
Asma' Ali
AJAbbe Maleyki Mhd Jalil
Abbe Maleyki Mhd Jalil
HYHayati Yusof
Hayati Yusof
MTMichelle Mun Chieng Tan
Michelle Mun Chieng Tan
Background and Objectives: Cognitive performance is essential for children, given this is a critical stage of brain growth and development. This systematic review and meta-analysis aimed to ascertain if physical activity or micronutrients impact cognitive performance in children. Materials and Methods: Electronic databases (PubMed and Scopus®) were searched for relevant articles published between 2012 and 2021. We emphasized randomized controlled trials (RCTs) that examined the effect of physical activity and micronutrients on cognitive performance. Data from eligible studies were gathered and evaluated using random-, fixed- or pooled-effects models with 95% confidence intervals (95% CI). Results: Physical activity appeared to improve both Mathematics (d = 1.12, 95% CI: 0.56, 1.67) and attention (d = 0.65, 95% CI: 0.15, 1.14) performances. The micronutrient vitamin B12 had a positive effect on Mathematics (d = 2.39, 95% CI: 0.79, 3.98), English (d = 5.29, 95% CI: 2.76, 7.83), Geography (d = 5.29, 95% CI: 2.76, 7.83), Science (d = 3.39, 95% CI: 2.62, 4.16) and Arts (d = 3.32, 95% CI: 1.84, 4.79). Zinc was found to positively affect English (d = 3.78, 95% CI: 0.44, 7.13), Geography (d = 4.77, 95% CI: 0.56, 8.98) and Arts (d = 2.39, CI: 0.33, 4.45). Iron positively affected Mathematics (d = 1.29, 95% CI: 0.54, 2.06), English (d = 1.29, 95% CI: 0.44, 7.13), Geography (d = 4.77, 95% CI: 0.56, 8.98) and Arts (d = 2.39, 95% CI: 0.33, 4.45). Conclusions: A more comprehensive intervention with a specific dose/level of physical activity, an increased range of cognitive performance, and a well-designed study design that accounts for dietary intake and other health outcomes are required for future studies.

20 September 2013 in Marine Drugs
Verified
Journal Article
Open access
PDF file
HYHayati Yusof
Hayati Yusof
ACAbbie L. Cawood
Abbie L. Cawood
RDRen Ding
Ren Ding
JWJennifer A. Williams
Jennifer A. Williams
FNFrances L. Napper
Frances L. Napper
PCPhilip Calder
Philip Calder
The objective of this study was to determine the effects of prescription omega-3 (n-3) fatty acid ethyl esters (Omacor®) on blood pressure, plasma lipids, and inflammatory marker concentrations in patients awaiting carotid endarterectomy. Patients awaiting carotid endarterectomy (n = 121) were randomised to Omacor® or olive oil as placebo (2 g/day) until surgery (median 21 days). Blood pressure, plasma lipids, and plasma inflammatory markers were determined. There were significant decreases in systolic and diastolic blood pressure and in plasma triglyceride, total cholesterol, low density lipoprotein-cholesterol, soluble vascular cellular adhesion molecule 1, and matrix metalloproteinase 2 concentrations, in both groups. The extent of triglyceride lowering was greater with Omacor® (25%) compared with placebo (9%). Soluble E-selectin concentration was significantly decreased in the Omacor® group but increased in the placebo group. At the end of the supplementation period there were no differences in blood pressure or in plasma lipid and inflammatory marker concentrations between the two groups. It is concluded that Omacor® given at 2 g/day for an average of 21 days to patients with advanced carotid atherosclerosis lowers triglycerides and soluble E-selectin concentrations, but has limited broad impact on the plasma lipid profile or on inflammatory markers. This may be because the duration of intervention was too short or the dose of n-3 fatty acids was too low.